Kamada Ltd. (NASDAQ:KMDA) Sees Large Drop in Short Interest

Kamada Ltd. (NASDAQ:KMDA) saw a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 39,600 shares, a decrease of 8.1% from the May 31st total of 43,100 shares. Based on an average daily volume of 17,500 shares, the short-interest ratio is currently 2.3 days. Approximately 0.1% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

KMDA has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Thursday, May 9th. StockNews.com initiated coverage on Kamada in a research report on Thursday, June 27th. They set a “buy” rating on the stock. Finally, Stifel Nicolaus initiated coverage on Kamada in a research report on Wednesday. They set a “buy” rating and a $18.00 price objective on the stock.

Institutional Trading of Kamada

Hedge funds have recently made changes to their positions in the stock. EWA LLC purchased a new position in Kamada in the 4th quarter worth approximately $68,000. Calton & Associates Inc. purchased a new position in Kamada in the 4th quarter worth approximately $111,000. Y.D. More Investments Ltd raised its holdings in Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 15,000 shares during the last quarter. Aristides Capital LLC raised its holdings in Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 16,635 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares during the last quarter. 20.38% of the stock is owned by institutional investors.

Kamada Stock Performance

Shares of KMDA traded up $0.19 during mid-day trading on Wednesday, reaching $5.19. The company had a trading volume of 94,194 shares, compared to its average volume of 21,015. The firm has a 50-day moving average price of $5.26 and a 200 day moving average price of $5.62. Kamada has a 52 week low of $4.08 and a 52 week high of $6.53. The company has a market capitalization of $298.32 million, a price-to-earnings ratio of 23.22 and a beta of 1.06.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). Kamada had a return on equity of 5.50% and a net margin of 8.33%. The company had revenue of $37.74 million during the quarter, compared to the consensus estimate of $38.01 million. As a group, research analysts forecast that Kamada will post 0.26 earnings per share for the current fiscal year.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.